Table 1—

Demographic and clinical characteristics of patients in the safety analyzable population (pooled data from 13 studies, N = 3,702)

Clinical featureNateglinideMetforminGlyburidePlacebo
All patients
n2,204436293769
 Age (years)59.2 ± 10.657.1 ± 10.359.5 ± 10.358.5 ± 10.8
 Duration diabetes (years)*5.1 ± 5.75.6 ± 5.86.7 ± 5.64.2 ± 4.6
 BMI (kg/m2)*29.1 ± 3.829.5 ± 4.028.8 ± 3.829.4 ± 3.7
 HbA1c (%)*7.8 ± 1.28.3 ± 1.18.1 ± 1.07.8 ± 1.2
 FPG (mmol/l)*9.6 ± 2.410.5 ± 2.410.5 ± 2.89.9 ± 2.5
 Serum creatinine (μmol/l)*91.5 ± 18.390.5 ± 14.787.7 ± 15.790.1 ± 17.1
 Clcr (ml/min per 1.73m2)*77.1 ± 20.080.1 ± 18.679.3 ± 21.779.1 ± 20.6
 Cardiovascular condition (%)47.549.543.348.1
 Microvascular condition (%)59.261.057.760.5
Patients >64 years
n73710492237
 Age (years)*70.6 ± 4.570.4 ± 4.071.4 ± 4.470.6 ± 4.3
 Duration diabetes (years)*6.5 ± 7.07.5 ± 7.38.7 ± 6.95.3 ± 5.4
 BMI (kg/m2)*28.4 ± 3.728.1 ± 4.027.7 ± 3.828.4 ± 3.8
 HbA1c (%)*7.6 ± 1.08.2 ± 1.07.9 ± 1.07.7 ± 1.1
 FPG (mmol/l)*9.2 ± 2.110.0 ± 2.110.0 ± 2.99.5 ± 2.2
 Serum creatinine (μmol/l)*96.4 ± 19.696.0 ± 15.291.3 ± 15.694.1 ± 16.8
 Clcr (ml/min per 1.73m2)*61.5 ± 12.461.1 ± 10.763.3 ± 14.962.8 ± 12.9
 No. (%) age ≥70 years387 ± 52.553 ± 51.058 ± 63.0119 ± 50.2
 Cardiovasclar condition (%)59.258.752.257.7
 Microvascular condition (%)70.472.867.469.2
Patients >64 years with RI
n3335188100
 Age (years)*72.9 ± 4.972.2 ± 4.474.2 ± 4.172.9 ± 4.7
 Duration diabetes (years)*7.1 ± 8.28.5 ± 6.58.6 ± 7.06.0 ± 6.0
 BMI (kg/m2)*27.2 ± 3.526.6 ± 3.326.8 ± 3.726.6 ± 3.6
 HbA1c (%)*7.5 ± 1.08.1 ± 1.07.8 ± 1.07.5 ± 1.1
 FPG (mmol/l)*8.9 ± 2.19.7 ± 2.19.4 ± 3.09.1 ± 2.0
 Serum creatinine (μmol/l)*108.0 ± 20.4104.1 ± 13.7101.5 ± 14.4105.3 ± 16.3
 Clcr (ml/min per 1.73m2)*50.9 ± 7.152.2 ± 5.450.6 ± 7.251.1 ± 6.4
 No. (%) age ≥70 years244 ± 73.334 ± 66.733 ± 86.869 ± 69.0
 Cardiovascular condition (%)64.954.571.160.3
 Microvascular condition (%)74.368.276.375.0
  • *

    * Data are means ± SD.

  • RI: calculated Clcr <60 ml/min per 1.73m2.